Other languages Celcuity Inc.

Equities

CELC

US15102K1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
18.79 ^USD	+5.74%		+11.65%	+28.96%

Jul. 01	Celcuity Inc.(NasdaqCM:CELC) added to Russell 3000 Growth Index	CI
Jul. 01	Celcuity Inc.(NasdaqCM:CELC) added to Russell Microcap Growth Index	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	May. 30
Celcuity Plans Phase 3 Trial of Potential Breast Cancer Therapy, Receives Additional Term Loan	May. 30
Celcuity Prices $60 Million Common Stock Offering	May. 30
Celcuity Inc. Announces Plan to Initiate A Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer	May. 30
Celcuity Q1 Net Loss Widens; Shares Rise After Hours	May. 15
Celcuity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Celcuity Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Celcuity Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	Feb. 22
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	Feb. 20
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	Dec. 06
Celcuity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-18
Sector Update: Health Care Stocks Sliding Wednesday Afternoon	23-10-18
Celcuity Launches $50 Million Private Placement; Shares Rise	23-10-18
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer	23-08-22
Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer	23-08-22
Celcuity Inc. Enters into Clinical Trial Collaboration and Supply Agreement with Bayer AG to Provide Nubeqa (Darolutamide) for Phase 1B/2 Clinical Trial	23-08-22
Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Celcuity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celcuity Inc.

Equities

CELC

US15102K1007

Other languages

Filters